Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases
Shweta Kotian, Lisa Zhang, Myriem Boufraqech, et al.
Clinical Cancer Research (2017) Vol. 23, Iss. 17, pp. 5044-5054
Open Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

Role of PI3K/AKT pathway in cancer: the framework of malignant behavior
Ningni Jiang, Qijie Dai, Xiaorui Su, et al.
Molecular Biology Reports (2020) Vol. 47, Iss. 6, pp. 4587-4629
Open Access | Times Cited: 471
The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
Li Guo, Yuan Tian, Wei‐Guo Zhu
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 269
Novel targeted therapies and immunotherapy for advanced thyroid cancers
George E. Naoum, Michael Morkos, Brian W. Kim, et al.
Molecular Cancer (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 207
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives
Robert Jenke, Nina Reßing, Finn K. Hansen, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 634-634
Open Access | Times Cited: 137
Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance?
Marta Szumilak, Anna Wiktorowska‐Owczarek, Andrzej Stańczak
Molecules (2021) Vol. 26, Iss. 9, pp. 2601-2601
Open Access | Times Cited: 119
New clinical trial design in precision medicine: discovery, development and direction
Xiao-Peng Duan, Bao‐Dong Qin, Xiao‐Dong Jiao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 51
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy
Tingting Liu, Yichao Wan, Yuliang Xiao, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 17, pp. 8977-9002
Closed Access | Times Cited: 130
Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer In Vitro and In Vivo
Shilpa Thakur, Brianna Daley, Kelli Gaskins, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 16, pp. 4030-4043
Open Access | Times Cited: 118
HDAC2 as a target for developing anti-cancer drugs
Hyein Jo, Kyeonghee Shim, Hanul Kim, et al.
Computational and Structural Biotechnology Journal (2023) Vol. 21, pp. 2048-2057
Open Access | Times Cited: 32
Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases
Kehui Zhang, Fangfang Lai, Songwen Lin, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 15, pp. 6992-7014
Closed Access | Times Cited: 67
SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression
Zhijie Zhang, Ni Qiu, Jiang Yin, et al.
Theranostics (2020) Vol. 10, Iss. 10, pp. 4290-4307
Open Access | Times Cited: 66
Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia
Xinyu Li, Yongwei Su, Gerard J. Madlambayan, et al.
Haematologica (2019) Vol. 104, Iss. 11, pp. 2225-2240
Open Access | Times Cited: 60
Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective
Yuan Gao, Hang Zhang, Frédéric Lirussi, et al.
Biochemical Pharmacology (2020) Vol. 182, pp. 114224-114224
Open Access | Times Cited: 60
Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review
Priyanka Singh, Veerandra Kumar, Sonu Gupta, et al.
Medical Oncology (2021) Vol. 38, Iss. 1
Closed Access | Times Cited: 49
Recent advances in multitarget-directed ligands via in silico drug discovery
Maddeboina Krishnaiah, Bharath Yada, Shikha Kumari, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 3, pp. 103904-103904
Closed Access | Times Cited: 6
Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma
Xinyi Cao, Lin Dang, Xiangqian Zheng, et al.
Thyroid (2019) Vol. 29, Iss. 6, pp. 809-823
Open Access | Times Cited: 52
Anticancer properties of chimeric HDAC and kinase inhibitors
Bernhard Biersack, Sibel Polat, Michael Höpfner
Seminars in Cancer Biology (2020) Vol. 83, pp. 472-486
Closed Access | Times Cited: 47
AURKB: a promising biomarker in clear cell renal cell carcinoma
Bangbei Wan, Yuan Huang, Bo Liu, et al.
PeerJ (2019) Vol. 7, pp. e7718-e7718
Open Access | Times Cited: 44
The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia
Xinyu Li, Yongwei Su, Katie Hege, et al.
Haematologica (2020) Vol. 106, Iss. 5, pp. 1262-1277
Open Access | Times Cited: 42
CUDC‐907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action
Cheng Hu, Hongyan Xia, Shanshan Bai, et al.
Journal of Cellular and Molecular Medicine (2020) Vol. 24, Iss. 13, pp. 7239-7253
Open Access | Times Cited: 42
An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives
Ma Su, Xing-Yu Gong, Feng Liu
Expert Opinion on Drug Discovery (2021) Vol. 16, Iss. 7, pp. 745-761
Closed Access | Times Cited: 33
Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases
Pei Shen, Yezhi Wang, Xiangxiang Jia, et al.
European Journal of Medicinal Chemistry (2022) Vol. 239, pp. 114551-114551
Closed Access | Times Cited: 27
Dual Targeting of PI3K and HDAC by CUDC-907 Inhibits Pediatric Neuroblastoma Growth
Rameswari Chilamakuri, Saurabh Agarwal
Cancers (2022) Vol. 14, Iss. 4, pp. 1067-1067
Open Access | Times Cited: 24
Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer
Milan Beljkaš, Aleksandra Ilić, Alen Cebzan, et al.
Pharmaceutics (2023) Vol. 15, Iss. 11, pp. 2581-2581
Open Access | Times Cited: 11
ICAM3 mediates inflammatory signaling to promote cancer cell stemness
Wenzhi Shen, Junling Xie, Shuangtao Zhao, et al.
Cancer Letters (2018) Vol. 422, pp. 29-43
Open Access | Times Cited: 35
Page 1 - Next Page

Scroll to top